drugset / Trial / NCT05004441

Fruquintinib Combined With mFOLFOX6/FOLFIRI in First-line Treatment for Metastatic Colorectal Cancer

NCT05004441

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of Fruquintinib Combined With mFOLFOX6/FOLFIRI as the first-line treatment of Metastatic Colorectal Cancer

Timeline

Start
2021-07-22
Primary completion
2022-12-30
Completion
2023-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Fruquintinib Small molecule 3 mg Oral

Indications